NCT07628998 Impact of SMS Messaging on Participation in Colorectal Cancer Screening.
| NCT ID | NCT07628998 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Corporacion Parc Tauli |
| Condition | Colorectal Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 10,084 participants |
| Start Date | 2026-05-05 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10,084 participants in total. It began in 2026-05-05 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colorectal cancer is a leading cause of mortality in Catalonia. Although early detection programs using the fecal immunochemical test (FIT) are effective in reducing both incidence and mortality, their success relies on high population participation. Currently, in the Vallès Occidental region, the participation rate stands at 42%, which is below the 65% minimum recommended by European health authorities. The objective of this randomized controlled trial is to evaluate whether sending a reminder text message (SMS) is an effective tool to increase participation in the screening program. The study will include 10,084 participants aged between 50 and 69 years. Half of the participants will receive a reminder SMS five weeks after their initial invitation, while the other half will follow the standard of care involving postal letters. Researchers anticipate that this strategy will not only increase the number of individuals undergoing screening but also shorten the response time and reduce the need for sending postal reminders.
Eligibility Criteria
Inclusion Criteria: * Women and men aged 50 to 69 years. * Residents of the Vallès Occidental area. * Individuals invited to the Colorectal Cancer Screening Program (PDPCCR) who have not participated within 5 weeks of the initial invitation. Exclusion Criteria: * Personal history of colorectal cancer. * Inflammatory bowel disease (IBD) * Colorectal polyps requiring specific clinical follow-up. * Hereditary polyposis syndromes. * High-risk family history of colorectal cancer: a first-degree relative diagnosed before age 50, or two or more first-degree relatives at any age. * Severe morbidity that precludes the performance of a colonoscopy in the event of a positive test result.
Contact & Investigator
Anna Selva Olid, PhD, MPH, MD
PRINCIPAL INVESTIGATOR
Corporación Parc Taulí
Frequently Asked Questions
Who can join the NCT07628998 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 69 Years, studying Colorectal Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07628998 currently recruiting?
Yes, NCT07628998 is actively recruiting participants. Contact the research team at aselva@tauli.cat for enrollment information.
Where is the NCT07628998 trial being conducted?
This trial is being conducted at Sabadell, Spain.
Who is sponsoring the NCT07628998 clinical trial?
NCT07628998 is sponsored by Corporacion Parc Tauli. The principal investigator is Anna Selva Olid, PhD, MPH, MD at Corporación Parc Taulí. The trial plans to enroll 10,084 participants.